Form 4: Catalyst Pharmaceuticals Chairman Sells 200,000 Shares for Personal Reasons

Patrick J. McEnany, Chairman of the Board and a 10% owner of Catalyst Pharmaceuticals, Inc., reported the sale of 200,000 shares of common stock for personal reasons, not due to any disagreement with the company.

Summary

• Patrick J. McEnany, who serves as Director, 10% Owner, and Chairman of the Board of Catalyst Pharmaceuticals, Inc. (CPRX), reported two separate sales of common stock.
• On June 6, 2025, Mr. McEnany sold 28,252 shares of common stock at a weighted average price of $25.945 per share, with prices ranging from $25.906 to $25.95.
• On June 9, 2025, an additional 171,748 shares of common stock were sold at a weighted average price of $26.11 per share, with prices ranging from $25.765 to $26.46.
• The total number of shares sold across both transactions amounts to 200,000.
• Following these transactions, Mr. McEnany beneficially owns 4,281,702 shares of Catalyst Pharmaceuticals common stock.
• The filing explicitly states that the shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the explicit statement that the sales were for 'personal reasons' and 'not as a result of any disagreement with the Company' mitigates potential negative interpretations, suggesting no underlying issues with the company's performance or strategy.

Positives

• The filing explicitly states that the sales were for personal reasons and not due to any disagreement with the Company, which can help mitigate concerns about the company's performance or strategic direction.

Negatives

• The sale of a significant number of shares (200,000) by a key insider, such as the Chairman and a 10% owner, reduces insider ownership and can sometimes be perceived negatively by the market, regardless of the stated reason.

Risks

• While stated as personal, significant insider selling can sometimes lead to market speculation or a temporary negative sentiment regarding the company's stock price.

Future Outlook

NA

Management Comments

• "Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company."

Industry Context

This Form 4 filing details an insider transaction, which is a routine disclosure for publicly traded companies. It does not provide information on broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders may observe a reduction in insider ownership by a key executive and significant shareholder, though the stated personal reasons for the sale aim to mitigate concerns about company performance or strategy.

Key Dates

Recommendation

Keywords

SEC Form 4, Insider Trading, Stock Sale, Catalyst Pharmaceuticals, CPRX, Patrick J. McEnany, Director, Chairman, Common Stock